Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Condition:   Non Small Cell Lung Cancer Intervention:   Drug: Pyrotinib Sponsor:   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials